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ABSTRACT
MicroRNA downregulation is frequent in malignant pleural mesothelioma (MPM), 
but the mechanisms responsible for loss of miR-15/16 and miR-193a are yet to be 
elucidated and were investigated in this study. Copy Number Variation (CNV) of 
microRNA-coding genes was analyzed in MPM cells by digital droplet PCR (ddPCR) 
and revealed heterozygous loss of miR-193a and miR-15a/16-1, but no change in miR-
15b/16-2. Epigenetic control of microRNA expression was inferred following decitabine 
and Trichostatin A (TSA) treatment which did not substantially affect microRNA 
expression. Knockdown of c-Myc expression led to upregulation of SMC4, miR-15b 
and 16, and to a lesser extent DLEU2 and miR-15a, whereas c-Myc overexpression 
repressed microRNA expression. Chromatin immunoprecipitation (ChIP) assays 
confirmed the interaction of c-Myc with the DLEU2 and SMC4 promoters. Tumor 
microRNA expression was determined in samples from MPM patients, with samples 
of pleura from cardiac surgery patients used as controls. In tumor samples, a strong 
correlation was observed between the expression of miR-15b and 16 (R2=0.793), 
but not miR-15a and 16. Our data suggest that in MPM, the downregulation of miR-
15/16 is due to transcriptional repression by c-Myc, primarily via control of the miR-
15b/16-2 locus, while miR-193a-3p loss is due to genomic deletion.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a 
cancer with very poor prognosis and asbestos exposure 
as the main risk factor, often developing 20-60 years after 
the date of first asbestos exposure [1]. Median overall 
survival ranges between 9 and 17 months regardless of 
stage and the combination of pemetrexed and cisplatin is 
the current standard of palliative care, offering a modest 
improvement in patient survival [2]. Attempts to improve 
disease outcome with targeted therapies were largely 
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unsuccessful [3], highlighting the essential requirement for 
an improved understanding of MPM biology to facilitate 
the development of effective therapies. Genetic profiling 
studies in MPM have identified the upregulation of genes 
involved in cell-cycle, proliferation and chemoresistance 
[4, 5] but effective means of attenuating their expression 
have not yet been determined. More recently targeting 
immune checkpoints using antibodies specific for the 
PD-1/PD-L1 axis have produced promising responses 
in mesothelioma patients [6]. However, compared to 
the successes observed in melanoma and lung cancer 
following immune checkpoint blockade [7], disease 
control is only observed in a fraction of mesothelioma 
patients in clinical trials with the majority of patients 
either relapsing or being refractory to treatment [8]. Poor 
response may be attributed in part to the low mutational 
load in MPM, which is considered an important 
determinant for immune checkpoint inhibition response in 
melanoma and lung cancer [6].
In addition to the changes in the expression of 
protein coding genes mentioned above, recent evidence 
implicates noncoding RNAs (ncRNAs) in many of 
the phenotypes of MPM cells. MicroRNAs (miRNAs) 
are an important family of short ncRNAs that post-
transcriptionally regulate gene expression through 
interaction with sites in the 3’ untranslated region 
(3’UTR) of target messenger RNAs (mRNAs). MiRNAs 
are initially transcribed as long primary microRNA 
transcripts (pri-miRNAs) by RNA polymerase II that are 
capped, polyadenylated [9, 10] and subjected to further 
processing in the nucleus and cytoplasm to generate a 
mature miRNA [11]. Multiple studies have identified 
frequent dysregulation of miRNAs in cancer, with many 
targeting mRNAs involved in tumor progression [12]. The 
altered expression profiles of miRNAs have assisted in 
the classification and prognosis of cancer and have been 
shown to promote tumorigenesis in many malignancies 
[13] including MPM [14, 15].
As in other malignancies a global downregulation 
of miRNAs is observed in MPM, with several 
microRNAs demonstrated to exhibit tumor suppressor 
activity [16, 17]. MiR-34b/c regulates cell cycle and 
apoptotic processes via regulation of multiple oncogenic 
targets including c-Met, CCND1, BCL2, and c-Myc and 
is downregulated by DNA methylation in approximately 
90% of MPM cases [14, 18]. In the case of miR-31, 
loss is via genomic deletion together with the adjacent 
CDKN2A gene and has been associated with tumor 
recurrence and aggression in MPM patients [19]. In 
contrast, the underlying mechanisms responsible for the 
majority of downregulated miRNAs in MPM are largely 
unknown. This includes for example, the downregulation 
of miR-15a/16-1 and miR-15b/16-2 that we recently 
demonstrated in MPM tumor samples and cell lines. 
While the anti-tumor functions of miR-15/16 in MPM 
have been well-characterized in vitro and in vivo [15] 
and showed promising response in the phase I clinical 
trial MesomiR-1 [20], the mechanism(s) leading to their 
downregulation has not been investigated. Similarly, 
we have also shown that re-expression miR-193a-3p – 
another miRNA consistently downregulated in MPM – 
not only induced apoptosis and reduced cell proliferation 
of MPM cell lines, but also inhibited MPM xenograft 
tumor growth to a similar extent as observed with miR-
16 [15]. Despite the association of the MIR193A gene 
promoter with CpG islands and its confirmed silencing 
by methylation in NSCLC [21] and acute myeloid 
leukemia (AML) [22], methylation was excluded as 
a predominant cause of its downregulation in MPM 
cell lines [23] and the causes for its reduction in MPM 
remain unknown.
In the current study, we aimed to characterize the 
mechanisms leading to miRNA downregulation in MPM 
cell lines by systematically determining whether defects 
occur at different stages of miRNA biogenesis. Results 
here provide evidence for the contribution of genomic 
deletion and transcriptional repression – but not epigenetic 
regulation – to the suppression of mature miR-15a/16-1, 
miR-15b/-16-2, and miR-193a-3p levels in MPM cell lines.
RESULTS
Genomic alterations of miRNA coding genes are 
observed in MPM
Copy number variation (CNV) was assessed using 
digital droplet PCR (ddPCR) in MPM cell lines (Figure 
1), revealing heterozygous loss of MIR15A/MIR16-1 in 
H2052 and H2452 cells (Figure 1A), but no deletion of 
MIR15B/MIR16-2 (Figure 1B). Levels of mature miR-
15a are consistently low in the MPM cell line panel [15] 
regardless of MIR15A/MIR16-1 CNV (data not shown), 
suggesting that gene dosage is not solely responsible for 
the reduced expression of mature miR-15a or miR-16 
from the MIR15A/MIR16-1 locus in MPM. Allelic loss of 
the MIR193A gene was observed in the majority of MPM 
cell lines tested (Figure 1C), suggesting that heterozygous 
deletion of the MIR193A region is a key contributor to 
downregulation of miR-193a-3p in MPM.
Epigenetic changes contribute little to 
downregulation of miR-15/16 and 193a in MPM 
cell lines
MiRNA expression was evaluated following 
treatment with the DNA methylation inhibitor decitabine 
or the pan-HDAC inhibitor TSA. Decitabine caused a 
distinct (~250-fold) upregulation of miR-34c (Figure 2A), 
a miRNA previously shown to be silenced via promoter 
hypermethylation in MPM [14]. In contrast, negligible 
changes in expression were observed for miR-15a, miR-
15b and miR-16 in most cells, however, the expression of 
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miR-15/16 is partially affected by decitabine treatment in 
H2052 and H2452, suggesting some regulation by DNA 
methylation in these cell lines (Figure 2A), whereas miR-
193a-3p expression was only slightly altered. Similarly, 
TSA treatment did not substantially alter expression of 
miR-15a, miR-15b, miR-16 or miR-193a-3p (Figure 2B). 
Collectively, this data suggest that methylation and histone 
deacetylation are unlikely to be major contributors to the 
loss of miR-15/16 or miR-193a-3p in MPM cell lines.
Downregulation of pri-miRNA and host gene 
expression in MPM cell lines
Both pri-miR-15a/16-1 and pri-miR-15b/16-2 
were downregulated in most of the MPM cell lines 
compared to MeT-5A (Figure 3A). Since pri-miR-
15a/16-1 and pri-miR-15b/16-2 are transcribed from 
the promoters of their host genes DLEU2 and SMC4 
respectively, we hypothesized that a transcriptional defect 
Figure 1: Analysis of copy number variation (CNV) of miRNA genes in MPM reveals allelic loss of the MIR193A and 
to a lesser extent MIR15A/16-1, but not MIR15B/MIR16-2. ddPCR was used to measure the endogenous genomic expression 
of miRNA coding genes in an MPM cell line panel (MSTO, H28, VMC23, H2052, H2452) as well as the mesothelial cell line MeT-5A. 
Genomic expression is presented here as copy number determined by normalization to the internal control gene ribonuclease P protein 
subunit p30 (RPP30). Copy number values of <2 were considered to indicate heterozygous deletion while a copy number <1 demonstrated 
homozygous loss. (A) No genomic loss of MIR15A/16-1 is determined for MSTO, H28, VMC23 and MeT-5A but heterozygous deletion is 
observed for H2052 and H2452. (B) No CNV is observed in cell lines for MIR15B/16-2. (C) Heterozygous loss of MIR193A was observed 
in H28, H2052, H2452 and MeT-5A. (D) MIR31 exhibits heterozygous deletion in H28 and homozygous deletion in H2452. MIR31 loss 
has previously been identified in H2452 and was included as a positive control for deletion in our cell line panel [19]. All data are the mean 
of 3 replicate experiments ± SEM.
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at these loci would affect both pri-miRNA and host gene 
expression. Similar to the observed reduction in pri-
miRNA expression, the transcription of DLEU2 – and 
to a greater extent SMC4 - was downregulated in MPM 
cell lines compared to the mesothelial cell line (Figure 
3B), further supporting a transcriptional mechanism of 
downregulation.
Knockdown of c-Myc upregulates miR-15b/16-2 
and inhibits cell growth
We next investigated the potential role of the 
oncogenic transcription factor Myc in miR-15/16 
inhibition, as it has been shown to suppress miRNA 
expression [24-26] and is upregulated in MPM partly 
due to increased copy number of the MYC gene [27]. To 
determine the effects of Myc on miR-15/16 expression 
in MPM, we knocked down Myc in MSTO and H28 
cells, with high and low Myc expression, respectively. 
Although basal levels of Myc were substantially higher 
in MSTO cells, expression in both cell lines was reduced 
significantly upon siRNA transfection (Figure 4A). Myc 
knockdown led to upregulation of miR-16 levels in 
MSTO (2-fold) and H28 (1.7-fold) compared to control 
transfected cells. In addition, Myc downregulation 
increased miR-15b (4.4 and 2-fold in MSTO and H28, 
respectively) but had little effect on miR-15a (Figure 
4B). As seen in Figure 4C, levels of pri-miR-15b were 
increased by 10.7-fold and 2.7-fold in MSTO and H28 
respectively following transfection with Myc siRNA 
while co-transcribed SMC4 was elevated by 5.9-fold 
in MSTO and 8.1-fold in H28 (Figure 4D). Conversely, 
levels of pri-miR-15a and DLEU2 showed a more 
modest increase in expression suggesting that Myc 
predominantly regulates the miR-15b/16-2 transcript 
in MPM. As Myc knockdown increased miR-15/16 
expression, and these miRNAs inhibit MPM growth 
in vitro and in vivo [15], we tested the effect of Myc 
knockdown in MPM cell line growth. Consistent with 
the effects of Myc on miR-15/16 expression, Myc 
knockdown significantly reduced proliferation of MSTO 
cells (Figure 4E).
Overexpression of Myc downregulates miR-
15b/16-2 and miR-15a/16-1 expression
Given the increase of miR-15b/16-2 and miR-
15a/16-1 expression following Myc knockdown, we 
set out to determine the effect of Myc upregulation. 
Using a MYC expression construct we transiently 
overexpressed Myc in the low expressing H28 cell line 
(Figure 5A). Transcription from both the miR-15b/16-2 
and miR-15a/16-1 loci were downregulated with Myc 
overexpression (Figure 5B), consistent with the direct 
regulation of miR-15/16 by Myc in MPM.
Myc interacts with the promoter regions of 
DLEU2 and SMC4 in MPM
Previous studies have demonstrated Myc binding 
to the promoter region of the DLEU2 gene that hosts 
the miR-15a/16-1 cluster [24, 28] but to our knowledge, 
no previous investigation has linked Myc to the 
transcriptional repression of SMC4, the host gene of the 
Figure 2: Epigenetic changes do not largely contribute to miR-15/16 downregulation in MPM cell lines. (A) Expression 
of miR-15a, 15b, 16, 193a-3p and 34c was determined by RT-qPCR after treatment of MPM cell lines with decitabine (Aza). A significant 
increase in miR-34c expression was evident following treatment but only subtle changes in expression were determined for miR-15a, miR-
15b, miR-16 and miR-193a-3p. (B) Changes in miRNA expression after 24 h of treatment with TSA (1 µM) was determined in cell lines 
by RT-qPCR. MiRNA expression in treated cells was compared to cells treated with a vehicle control and normalized to RNU6B. All data 
are the mean of 3 replicate experiments ± SEM. * = p ≤ 0.05; ** = p ≤ 0.01.
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Figure 3: The pattern of expression of miRNA processing intermediates suggest a defect in the transcription of 
miR-15/16 primary transcripts. RT-qPCR was used to test the endogenous expression of miR-15/16 processing intermediates 
including host gene mRNA/lncRNA and pri-miRNA expression in the MPM cell line panel. (A) pri-miR-15a and pri-miR-15b also 
show downregulated expression in all MPM cell lines compared to MeT-5A (red dotted line). (B) host genes DLEU2 and SMC4 are 
transcribed with miR-15a/16-1 and miR-15b/-16-2 respectively and show downregulated expression in MPM cell lines compared to 
MeT-5A. Expression values were normalized to 18S expression, and are relative to levels in MeT-5A. Results are the mean of 3 
biological replicates ± SEM. ** = p ≤ 0.01.
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miR-15b/16-2 cluster. To investigate the role of Myc 
in controlling transcription of miR-15a/16-1 and miR-
15b/16-2, we performed chromatin immunoprecipitation 
(ChIP) experiments and determined enrichment of 
regions in the DLEU2 and SMC4 promoters (shown 
schematically in Figure 5C). ChIP-qPCR analysis 
confirmed the association of the Myc protein with the 
SMC4 promoter region as seen by 30-fold enrichment of 
the SMC4 INR/S amplicons in MSTO and 11-fold in H28 
(Figure 5D). Similarly, amplicons S, 1A and 1B designed 
to span the DLEU2 promoter region produced 50-, 35- 
and 72-fold enrichment respectively following Myc 
immunoprecipitation. In amplicons S and 1B enrichment 
was markedly higher in MSTO samples compared to 
H28 (Figure 5D), probably due to the higher basal Myc 
expression in MSTO (Figure 4A). Together, these results 
support a direct interaction between Myc and both the 
miR-15a/16-1 and miR-15b/16-2 cluster in MPM.
Figure 4: Myc knockdown causes an upregulation of mature miR-15b/16-2 expression and its processing intermediates 
and inhibits cell growth. (A) Myc protein expression in MPM cell lines with high (MSTO) and low (H28) basal expression 48 h post 
transfection with Myc siRNAs (si-Myc-2 and si-Myc-4) and control (all at 20 nM). β-actin expression was included as a loading control. 
Densitometry was used to quantify Myc protein expression from 3 independent experiments that were normalized to β-actin. Data are mean 
±SD. RT-qPCR was used to measure (B) Mature miRNA, (C) pri-miRNA and (D) host gene mRNA expression levels following transfection 
with Myc siRNA (si-Myc-2, si-Myc-4) or control transfection. RNU6B was used as a reference gene for miRNA expression while 18s was 
used as reference for pri-miRNA and host-gene expression. Data is the mean from 3 separate experiments ±SD. (E) Cell proliferation was 
measured 96 h after transfection with si-Myc-2 or control at the indicated concentrations. Cell proliferation is represented as % of untransfected 
cells. Data is expressed as the mean ±SEM of 3 independent experiments performed in duplicate. * = p ≤ 0.05; ** = p ≤ 0.01.
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The expression of miR-15b and miR-16 is highly 
correlated in MPM tumor samples
Previously we showed that miR-15a, 15b, and 16 
were significantly (4 to 22-fold) downregulated in MPM 
tumors compared with normal pleura [15]. Comparing 
expression data for each of these miRNAs in individual 
samples in this data set revealed a strong correlation 
between miR-15b and 16 (R2=0.793) (Figure 6B), but 
not between miR-15a and miR-16 (Figure 6A). As a 
comparison, we analyzed expression of the miR-34 
family members in the same samples and found that all 
were downregulated as shown in Supplementary Figure 1 
[miR-34a (1.6-fold, P<0.05), 34b (1.8-fold, P<0.01), 34c 
Figure 5: MYC overexpression causes downregulation of miR-15b/16-2 and miR-15a/16-1 and their host genes via 
binding to the DLEU2 and SMC4 promoters. (A) H28 cells were transfected with pcDNA3.1(+) and pcDNA3.1(+)MYC plasmids 
and upregulation of Myc protein expression was confirmed via western blotting with β-actin included as a loading control and normalizer 
for densitometry. Data are the mean of 3 independent experiments ±SD. (B) Mature miRNA, pri-miRNA and host gene expression was 
analyzed using RT-qPCR with RNU6B and 18S as reference genes. MYC construct transfection induced downregulation of mature, pri- 
and host gene mRNAs from both the miR-15a/16-1 and miR-15b/16-2 clusters compared to vector control-transfected cells. Data are the 
mean of 3 independent experiments ±SD. * = p ≤ 0.05; ** = p ≤ 0.01. (C) Schematic representation of the promoter regions of the host genes 
DLEU2 and SMC4 with the amplicon locations used for ChIP analysis indicated below each gene. (D) ChIP was performed using a c-Myc 
antibody to detect binding to DNA within the DLEU2 and SMC4 promoter regions. DNA enrichment in chromatin immunoprecipitated 
by the c-Myc antibody was determined by Real-Time PCR. Relative fold-enrichment was then determined by comparing the enrichment 
with c-Myc antibodies to the enrichment for the no antibody control (Relative enrichment = sample enrichment (Myc)/sample enrichment 
(no antibody)). A negative control for Myc binding was included that corresponded to a region in chromosome 1 (chr1:204,366,822-
204,366,872). Data are mean ±SEM from 3 independent measurements.
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(2.3-fold, P<0.0001)]. For the miR-34 family, expression 
of the co-transcribed miR-34b and 34c showed substantial 
correlation (R2=0.753) (Figure 6D), whereas miR-34a and 
34b did not (Figure 6C).
DISCUSSION
Multiple studies have demonstrated global 
downregulation of miRNA expression in MPM [16], but 
the underlying mechanisms driving deregulated miRNA 
expression in MPM remain largely uncharacterized. 
MiRNAs are frequently located in genomic regions known 
to be altered in cancer, including minimal regions of loss 
of heterozygosity (LOH) and amplification as well as 
fragile sites and breakpoint regions [29]. Copy number 
alterations in the 13q14 chromosomal region, where miR-
15a/16-1 reside, were identified in more than 50% of B-cell 
chronic lymphocytic leukemia (B-CLL) tumors resulting 
in loss of mature miRNA expression [30]. In a genome 
wide study, approximately 25% of both ovarian and breast 
cancer specimens exhibited copy number loss of regions 
containing mir-15a and mir-16-1 [31]. Similarly, the miR-
15a/16-1 locus exhibits LOH in NSCLC tumor samples 
[32] and is frequently deleted in pituitary tumors [33]. Our 
data are somewhat consistent with these findings; using 
CNV analysis, we found heterozygous loss of MIR15A/16-1 
in H2452 and H2052 but not in the other MPM cell lines 
tested. In contrast, no deletions were found in the alternative 
miR-16 cluster, MIR15B/16-2 on chromosome 3q25, in any 
of the MPM cell line panel. Collectively these data suggest 
that other mechanisms are also accountable for miR-
15a/16-1 and miR-15b/16-2 loss in MPM. In comparison, 
the majority of cell lines were found to have deletion of one 
allele of the MIR193A locus, therefore attributing loss of 
mature miR-193a-3p expression to genomic deletion of its 
coding region in MPM.
Figure 6: The expression of miR-15b and miR-16 is highly correlated in MPM tumor samples. MiRNA expression in 
FFPE tumor samples (n=60) obtained from patients undergoing EPP were correlated using a linear regression model in Graphpad prism 
v7. RT-qPCR was used to determine raw Cq values to show correlation of: (A) miR-16 and miR-15a (R2 correlation coefficient value of 
0.3744), (B) miR-16 and miR-15b (R2 correlation coefficient value of 0.7931), (C) miR-34a and miR-34c (R2 correlation coefficient value 
of 0.2218), and (D) miR-34b and miR-34c (R2 correlation coefficient value of 0.7536).
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Epigenetic changes frequently modulate miRNA 
expression in cancer [34]. Family members miR-34b and 
miR-34c are inactivated due to CpG methylation in patients 
with colorectal, pancreatic, mammary, ovarian, urothelial, 
and renal cell carcinomas and soft tissue sarcomas [35]. 
In MPM, 85% of tumors exhibited increased methylation 
of the miR-34b/c promoter [14], and this methylation-
induced loss of miR-34c in MPM was confirmed here 
by the dramatic increases in miR-34c expression in the 
MPM cell line panel following treatment with the DNMT 
inhibitor decitabine. In contrast, the hypermethylation 
of the MIR193A gene promoter region found in lung 
cancer [21], AML [36] and ovarian cancer [37] does not 
appear to contribute to miR-193a-3p downregulation in 
MPM, as we have suggested previously [23]. Instead, 
miR-193a-3p loss in MPM cell lines appears to be the 
result of genomic deletion. Similarly, expression of miR-
15a/16-1 and miR-15b/16-2 changed little in response to 
DNMT inhibition. These miRNAs were also unaltered 
in cell lines treated with the HDAC inhibitor TSA. This 
contrasts with results reported for MCL and CLL, where 
miR-15a/16-1 transcription was increased by the addition 
of histone deacetylase inhibitors [38, 39]. Collectively, 
this data suggests that epigenetic modifications are not a 
predominant cause of the substantial reduction of miR-
15a, 15b and 16 expression in MPM cell lines and tumors.
Having excluded epigenetic modifications as 
predominant mechanisms causing miRNA loss in 
MPM cell lines, altered transcription factor activity was 
examined as a mechanism that could repress miRNA 
transcription, as found in other cancers [34]. Recently, 
DNA copy number analysis revealed frequent genomic 
amplification of the MYC gene in MPM tumor samples and 
cell lines [27]. c-Myc has integral roles in tumorigenesis 
by controlling genes involved in cell growth [24, 40] and 
is also implicated in the transcriptional control of miRNA 
expression [39]. Although Myc is regularly involved in 
the activation of gene expression, and promotes expression 
of the oncogenic miR-17-92 cluster in B-cell lymphoma, 
lung cancer [41] and chronic myeloid leukemia (CML) 
[42], it has become increasingly clear that Myc directly 
represses multiple miRNAs in cancer [26, 40, 41, 43, 
44]. For example, Myc induced widespread repression 
of multiple miRNAs in B-cell Lymphoma, including the 
tumor suppressors miR-15a/16-1, miR-34a and let-7, via 
direct association with their promoter regions [24]. Myc 
has been implicated in the transcriptional repression of 
miR-15a/16-1 expression in B-Cell Lymphoma [24, 39], 
Ewing’s sarcoma [26] and colorectal carcinoma [25], and 
was also shown to interact with HDAC3 to indirectly 
repress expression of miR-15a/16-1 in Mantle Cell 
Lymphoma (MCL) [39].
In this study we demonstrated Myc mediated 
repression of both the miR-15a/16-1 and miR-15b/16-2 
clusters. Interestingly, Myc reduction led to dramatic 
increases in expression from the miR-15b/16-2 region 
compared with more subtle differences seen for miR-
15a/16-1. When activating transcription, Myc and its 
binding partner Max dimerize before binding to gene 
promoter regions or within the first introns of target gene 
DNA via canonical DNA binding sites [45]. Alternatively, 
during transcriptional repression, Myc associates with 
core promoter regions via protein-protein interactions, 
where it inhibits positive regulators of transcription [45, 
46]. Myc can repress transcription through initiator (Inr) 
elements in start sites and interaction with promoter-bound 
transcription factors such as Miz1, Sp1 and Smads [45, 
47, 48]. In MPM cell lines, direct association of Myc with 
the miR-15a/16-1 cluster was demonstrated by enrichment 
of the DLEU2 promoter regions as described in previous 
studies [24-26, 39]. Unlike DLEU2, the SMC4 (miR-
15b/16-2) promoter region does not contain predicted 
Myc binding regions and Myc enrichment was instead 
identified in regions that are known to harbor Inr sites 
as examined by promoter regulation prediction software 
(YAPP, MAPPER2). In addition, data from MPM tumor 
samples indicated a stronger correlation between miR-
15b and miR-16 than between miR-15a and miR-16. As 
miR-15b is downregulated to a greater extent than miR-
15a in MPM tumors [15], and Myc has a greater effect 
on the miR-15b/16-2 locus, this suggests that the role 
played by Myc in the reduction of miR-16 in MPM occurs 
predominantly via suppression of the miR-15b/16-2 locus.
Myc exerts its oncogenic effects by regulating 
target genes that have roles in multiple processes 
including apoptosis and cell growth [39], and the dose-
dependent reduction in MPM cell line proliferation 
we observe after Myc knockdown suggests that Myc 
plays a similar role in MPM cell lines. Previously, we 
and others have shown that restoring expression levels 
of the miR-15/16 family results in similar cellular 
consequences to Myc knockdown [15, 49], so it is likely 
that increased miR-15/16 expression contributes to the 
effects on proliferation seen following Myc silencing. In 
addition to inhibition of MPM cell growth, miR-15/16 
suppression may also contribute to other Myc-mediated 
effects. For example, tumor-specific inactivation of Myc 
expression was shown to reverse immune evasion by 
preventing the Myc-induced transcriptional activation 
of PD-L1 and CD47 [50]. Although Myc was shown to 
bind the promoters of both genes, it is likely that Myc-
induced miRNA suppression also plays a role as miR-
15a, 15b and 16 directly regulate PD-L1 expression [51, 
52], and furthermore, Myc expression correlates with 
PD-L1 expression in lung cancer [53]. In this study, 
patients with tumors positive for both proteins had the 
poorest prognosis, leading the authors to speculate that 
Myc expression could serve as a surrogate marker for 
treatment response. Whether Myc expression influences 
response to immunotherapy involving checkpoint 
inhibitors and has value as a biomarker in MPM requires 
further investigation.
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MATERIALS AND METHODS
Cell lines and cell culture
The MPM cell lines MSTO-211H, H28, H2052, 
H2452, and the immortalized mesothelial cell line MeT-
5A were purchased from the American Type Culture 
Collection (Manassas, VA, USA). The VMC23 cell line 
was a kind gift from Prof Walter Berger (Institute of 
Cancer Research, Medical University of Vienna, Austria). 
All cell lines were cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum (both from Thermo Fisher 
Scientific, Carlsbad, CA, USA) at 5% CO2, 37°C and 95% 
humidity.
Patient samples
This study analyzed tumor samples from a 
previously reported series of MPM patients who 
underwent extrapleural pneumonectomy (EPP)[15]. 
This work was approved by the Human Research Ethics 
Committee (HREC) at Concord Repatriation General 
Hospital, Sydney (CH62/6/2009/078). Formalin-fixed 
normal pleural tissue (n=23) was collected from patients 
undergoing cardiac or aortic surgery as described [15], as 
part of a study approved by the HREC at RPAH (X10-
0342). Written informed consent was obtained from all 
participants.
Genomic DNA extraction and CNV analysis 
using ddPCR
Genomic DNA (gDNA) was collected from MPM 
cell lines using the QIAamp DNA mini kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instructions 
and quantified using a nanophotometer (Implen, Munich, 
Germany). CNV of the miRNA coding regions was 
determined by amplifying 40 ng of gDNA with specific 
primers (35 nM each, listed in Supplementary Table 1) 
multiplexed with the RPP30 reference gene and Evagreen 
chemistry using the Bio-Rad QX200™ ddPCR™ system 
(all Bio-Rad Laboratories, Munich, Germany). (See 
supplementary information for detailed methods).
Decitabine (5′Aza-2′deoxycitidine; 5′Aza-CdR) 
and Trichostatin A (TSA) treatment
MPM cell lines were grown to approximately 25% 
confluence in 5 cm cell culture dishes and then treated 
with decitabine (5′Aza-CdR; final concentration 5 μM) 
or vehicle (equivalent volume; 0.1% DMSO) every 24 h 
for a total of 120 h of continuous treatment. Treatment 
with Trichostatin A (TSA) commenced 24 h after cells 
were seeded at a concentration of 1.5 × 105 in 5 cm cell 
culture dishes and involved 24 h of exposure to TSA at a 
final concentration of 1 µM or vehicle (equivalent to 0.05 
% DMSO). On completion of drug treatment, changes 
in miRNA expression were determined by RT-qPCR as 
described in section 2.5.
Real-time RT-qPCR
RNA was extracted from MPM cell lines using 
TRIzol (Thermo Fisher Scientific) as per manufacturer’s 
instructions, and from laser-capture microdissected FFPE 
sections as described previously [15]. RNA was quantified 
using a nanophotometer and stored at -80°C prior to 
cDNA synthesis. MiRNA was quantified by RT-qPCR 
as described previously for cell lines and tumor samples 
[15] using the 2-ΔΔCq method [54] (See supplementary 
information for detailed methods).
siRNA transfection
C-Myc and control siRNAs were purchased 
from GenePharma (Shanghai, China; sequences in 
Supplementary Table 1). Cells were reverse-transfected 
with siRNAs using Lipofectamine RNAiMAX (Thermo 
Fisher Scientific) as described previously [55]. Briefly, 
siRNAs were applied at a final concentration of 20 nM for 
expression analysis and at 2-fold serial dilutions starting 
at 15 nM for determination of cell proliferation. RNA 
was isolated 24 h and protein 48 h after transfection with 
siRNAs.
Western blot
Cells were reverse-transfected with siRNAs in 
6-well plates as described above and 48 h later protein 
was isolated in RIPA buffer and quantified using the Pierce 
BCA protein assay kit (Thermo Fisher Scientific). Protein 
expression was measured by SDS-PAGE electrophoresis 
and Western immunoblotting with a c-Myc antibody 
(D3N8F; Cell Signaling, Danvers, MA) diluted 1:1000 
in blocking buffer overnight at 4°C. Membranes were 
stripped before probing with a Beta-actin (β-actin) 
antibody (AC-74, Sigma Aldrich, St. Louis, MO) as a 
control for protein loading. Chemiluminescence (Clarity 
Western ECL substrate, Bio-Rad), was used to image 
bands using the Gel Logic 2200 Imaging system (Kodak, 
New York, USA). (See supplementary information for 
detailed methods).
Generation of a c-Myc expression construct
The coding sequence (CDS) of the c-Myc mRNA 
(corresponding to the RefSeq entry NM_002467.4) was 
cloned from total RNA isolated from MSTO cells. The 
Promega MMLV RT kit was used to reverse transcribe 500 
ng total RNA, after which 40 ng of cDNA was amplified 
using AmpliTaq Gold 360 (Promega) with primers 
corresponding to the c-Myc CDS (Supplementary Table 
1). The resultant PCR amplicon was cloned into the TOPO 
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TA vector (Thermo Fisher Scientific) as outlined by the 
manufacturer and then sub-cloned into the pcDNA3.1 
expression vector (Thermo Fisher Scientific) after 
sequence confirmation by Sanger sequencing (Ramaciotti 
Centre, UNSW, Sydney).
Transient transfections with expression construct 
plasmids
Plasmids (pcDNA3.1(+)MYC or pcDNA3.1(+)) 
were introduced into H28 cells by forward transfection 
with the FuGene transfection reagent (Promega) as per 
the manufacturer's instructions. RNA was isolated 24 h, 
and protein 48 h, post transfection. (See supplementary 
information for detailed methods).
Chromatin immunoprecipitation (ChIP) qPCR
MSTO and H28 cells were analyzed by ChIP to 
determine the association of c-Myc with miR-15/16 
promoter regions. DNA isolated from untreated cells 
was subjected to ChIP using the c-Myc antibody with 
the EZ-ChIP Chromatin Immunoprecipitation Assay kit 
(Merck-Millipore, Darmstadt, Germany) according to the 
manufacturer's instructions. qPCR was carried out on the 
ViiA7 Real Time System with multiple sets of primers 
specific for the miR-15a/16-1 and miR-15b/16-2 promoter 
regions as well as a negative control for Myc binding 
(Supplementary Table 1). Sample enrichment was first 
evaluated relative to the input (Sample enrichment=2^[Ct 
input – Ct IP sample]), after which fold-enrichment 
was calculated by comparing the enrichment with Myc 
antibodies to the enrichment for the no-antibody control 
(Relative enrichment = sample enrichment [Myc IP]/
sample enrichment [no antibody]). (See supplementary 
information for detailed methods).
Cell proliferation assays
The effect of Myc knockdown on the 
proliferation of MPM cell lines was carried out 
using SYBR Green-based cell proliferation assays as 
described [15]. Briefly, cells were seeded at a density 
of 2.5 × 103 per well in a 96-well plate and reverse-
transfected with 30 nM or 60 nM Myc and control 
siRNAs. After freezing plates at -80°C, proliferation 
was measured by adding 150 µL of SYBR Green-
containing lysis buffer [55] to wells and incubating 
at 4°C overnight. Plates were equilibrated at room 
temperature before fluorescence was read on a 
FLUOstar OPTIMA microplate reader (BMG Labtech, 
Offenburg, Germany).
Statistical analysis
Differences in gene expression in cell lines 
and tumor samples were analyzed with a two-tailed 
independent samples t-test. Mann-Whitney U test was 
used to assess differences in cell proliferation. Analyses 
were performed using SPSS Statistics version 25 
(IBM Corp., Armonk, NY) and a P-value of ≤0.05 was 
considered statistically significant. The correlation of 
tumor miRNA expression was assessed by computing 
Pearson’s correlation coefficient of linear regression data 
in Graphpad Prism version 7.0b.
CONCLUSIONS
In summary, our data provide evidence for the 
contribution of multiple mechanisms in the downregulation 
of tumor suppressor miRNAs in MPM. A combination of 
genomic deletion and transcriptional repression – rather 
than hypermethylation – contribute to miR-193a, miR-
15a/16-1 and miR-15b/16-2 downregulation. Additionally, 
the mechanisms responsible for suppression of specific 
miRNAs appear to differ in MPM compared with other 
malignancies. Interestingly, in MPM, Myc seems to 
regulate miR-15/16 expression primarily via control of 
the miR-15b/16-2 locus. This data suggests that regulation 
of miR-15/16 may be an important contributor to the 
oncogenic activity of Myc in MPM [25, 26, 39].
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